| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5859006 | ELI LILLY CO | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(6 years ago) | |
|
US5859006 (Pediatric) | ELI LILLY CO | Tetracyclic derivatives; process of preparation and use |
May, 2018
(5 years ago) | |
| US7182958 | ELI LILLY CO | β-carboline pharmaceutical compositions |
Apr, 2020
(4 years ago) | |
|
US7182958 (Pediatric) | ELI LILLY CO | β-carboline pharmaceutical compositions |
Oct, 2020
(3 years ago) | |
| US6821975 | ELI LILLY CO | Beta-carboline drug products |
Nov, 2020
(3 years ago) | |
|
US6821975 (Pediatric) | ELI LILLY CO | Beta-carboline drug products |
May, 2021
(2 years ago) | |
Adcirca is owned by Eli Lilly Co.
Adcirca contains Tadalafil.
Adcirca has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Adcirca are:
- US5859006
- US5859006*PED
- US7182958
- US7182958*PED
- US6821975
- US6821975*PED
Adcirca was authorised for market use on 22 May, 2009.
Adcirca is available in tablet;oral dosage forms.
Adcirca can be used as treatment of pulmonary hypertension.
The generics of Adcirca are possible to be released after 19 May, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2012 |
| Orphan Drug Exclusivity(ODE) | May 22, 2016 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 22 May, 2009
Treatment: Treatment of pulmonary hypertension
Dosage: TABLET;ORAL
How can I launch a generic of ADCIRCA before it's drug patent expiration?
More Information on Dosage
ADCIRCA family patents
